Binding of Organometallic Ruthenium(II) Anticancer Compounds to Nucleobases: A Computational Study

被引:34
作者
Gossens, Christian [1 ]
Tavernelli, Ivano [1 ]
Rothlisberger, Ursula [1 ]
机构
[1] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
IN-VITRO; ANTITUMOR DRUGS; ARENE COMPLEXES; PTA COMPLEXES; DNA-BINDING; CANCER; INHIBITION; MECHANISMS; CISPLATIN; LIGAND;
D O I
10.1021/jp903237w
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
The reaction of the anticancer compound [(eta(6)-benzene)Ru(en)(OH2)](2+) (1) toward the nucleobases guanine, adenine, and cytosine is studied computationally using DFT/BP86 calculations. The aqua leaving group of such compounds is known to undergo ligand exchange reactions with nucleophilic centers in DNA and preferentially with the N7 atom of guanine, N7(G). Our results show that an H-bonded reactant adduct with nucleobases is formed via either the aqua ligand (cis adduct) or the en (ethylenediamine) ligand (trans adduct) of 1. All studied nucleobases favor an H-bonded cis adduct. Only guanine forms also a trans reactant adduct in the gas phase. The guanine N7 and O6 atoms in this trans adduct are situated in an ideal position to form each a strong H-bond to both amino groups of the en ligand of 1. A docking study shows that this unique recognition pattern is also plausible for the interaction with double stranded DNA. For the reaction of 1 with guanine, we identified three different reaction pathways: (i) A cis (G)N7-Ru-OH2 transition state (TS). (ii) A direct trans reaction pathway. (iii) A 2-step trans mechanism. The activation energies for the cis pathway are smaller than for the trans pathways. The ultimately formed Ru-N7(G) product is characterized by a thermally stable H-bond between the O6(G) and a diamine-NH2 hydrogen.
引用
收藏
页码:11888 / 11897
页数:10
相关论文
共 51 条
[1]   In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].
Aird, RE ;
Cummings, J ;
Ritchie, AA ;
Muir, M ;
Morris, RE ;
Chen, H ;
Sadler, PJ ;
Jodrell, DI .
BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657
[2]   Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R = H, Me; PTA=1,3,5-triaza-7-phosphaadamantane) [J].
Akbayeva, DN ;
Gonsalvi, L ;
Oberhauser, W ;
Peruzzini, M ;
Vizza, F ;
Brüggeller, P ;
Romerosa, A ;
Sava, G ;
Bergamo, A .
CHEMICAL COMMUNICATIONS, 2003, (02) :264-265
[3]  
Allardyce CS, 2001, PLATIN MET REV, V45, P62
[4]   [Ru(η6-p-cymene)Cl2(pta)] (pta=1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane):: a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells [J].
Allardyce, CS ;
Dyson, PJ ;
Ellis, DJ ;
Heath, SL .
CHEMICAL COMMUNICATIONS, 2001, (15) :1396-1397
[5]   DENSITY-FUNCTIONAL EXCHANGE-ENERGY APPROXIMATION WITH CORRECT ASYMPTOTIC-BEHAVIOR [J].
BECKE, AD .
PHYSICAL REVIEW A, 1988, 38 (06) :3098-3100
[6]   Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: Novel recognition mechanisms [J].
Chen, HM ;
Parkinson, JA ;
Morris, RE ;
Sadler, PJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (01) :173-186
[7]   Organometallic ruthenium(II) diamine anticancer complexes: Arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts [J].
Chen, HM ;
Parkinson, JA ;
Parsons, S ;
Coxall, RA ;
Gould, RO ;
Sadler, PJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (12) :3064-3082
[8]   Non-platinum chemotherapeutic metallopharmaceuticals [J].
Clarke, MJ ;
Zhu, FC ;
Frasca, DR .
CHEMICAL REVIEWS, 1999, 99 (09) :2511-2533
[9]  
COLOMBO MC, MODELLING MOL STRUCT, P85
[10]   In silico evolution of substrate selectivity:: comparison of organometallic ruthenium complexes with the anticancer drug cisplatin [J].
Deubel, Dirk V. ;
Lau, Justin Kai-Chi .
CHEMICAL COMMUNICATIONS, 2006, (23) :2451-2453